01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
A consensual affair between a superior and subordinate can advance to a quid pro quo harassment clai...
Read More >
Should highly compensated paralegals (likely more experienced paralegals) receive overtime pay? The ...
Read More >
On January 28, 2020, the Federal Trade Commission announced revised notification thresholds pursuant...
Read More >
On Feb. 3, the Federal Trade Commission (FTC) challenged Edgewell Personal Care’s proposed $1.37 bi...
Read More >
As you may have heard, Immigration and Customs Enforcement (“ICE”) plans to begin the previously p...
Read More >
Last year towards the end of May, a barrage of emails and pop-ups informed online users about how co...
Read More >